Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
20-23 May, 2025
Not Confirmed
Not Confirmed
21-23 May, 2025
Not Confirmed
Not Confirmed
21-23 May, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
20-23 May, 2025
Industry Trade Show
Not Confirmed
21-23 May, 2025
Industry Trade Show
Not Confirmed
21-23 May, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/us-drug-shortages-reduce-16-yoy-in-q1-2025-cns-drugs-antimicrobials-face-highest-scarcities
05 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250505207130/en/CORCEPT-THERAPEUTICS-ANNOUNCES-FIRST-QUARTER-FINANCIAL-RESULTS-AND-PROVIDES-CORPORATE-UPDATE
28 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250428138745/en/CORCEPT-THERAPEUTICS-TO-ANNOUNCE-FIRST-QUARTER-FINANCIAL-RESULTS-PROVIDE-CORPORATE-UPDATE-AND-HOST-CONFERENCE-CALL
23 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250422468615/en/CORCEPT-TO-PRESENT-LATE-BREAKING-DATA-FROM-PIVOTAL-PHASE-3-ROSELLA-TRIAL-OF-RELACORILANT-IN-PLATINUM-RESISTANT-OVARIAN-CANCER-AT-ASCO-2025
21 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250421854008/en/Diabetes-Care-Publishes-Results-From-Prevalence-Phase-Of-Corcepts-CATALYST-Trial-In-People-With-Difficult-To-Control-Type-2-Diabetes
07 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250407805321/en/Corcept-Initiates-Trial-of-Relacorilant-Plus-Nab-Paclitaxel-and-Bevacizumab-in-Patients-With-Platinum-Resistant-Ovarian-Cancer
01 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250331748780/en/Primary-Endpoint-Met-in-Corcepts-Pivotal-Phase-3-ROSELLA-Trial-of-Relacorilant-in-Patients-with-Platinum-Resistant-Ovarian-Cancer
ABOUT THIS PAGE